{"id":4014,"date":"2021-11-11T18:43:55","date_gmt":"2021-11-11T18:43:55","guid":{"rendered":"https:\/\/biotechsa.com\/2\/?p=4014"},"modified":"2026-03-10T13:01:17","modified_gmt":"2026-03-10T19:01:17","slug":"antibiotic-resistance-is-at-a-crisis-point-government-support-for-academia-and-big-pharma-to-find-new-drugs-could-help-defeat-superbugs","status":"publish","type":"post","link":"https:\/\/biotechsa.com\/2\/noticias\/antibiotic-resistance-is-at-a-crisis-point-government-support-for-academia-and-big-pharma-to-find-new-drugs-could-help-defeat-superbugs\/","title":{"rendered":"Antibiotic resistance is at a crisis point \u2013 government support for academia and Big Pharma to find new drugs could help defeat superbugs"},"content":{"rendered":"\n
<\/span><\/div>

In an article recently published on The Conversation, Professor Andre Hudson who is Head of the Thomas H. Gosnell School of Life Sciences at the Rochester Institute of Technology, detailed the steps he believes are important to combat the increasing antibiotic resistance crisis we face today. Antibiotic-resistant infections account for 700,000 deaths annually around the globe and according to a joint report by the United Nations and World Health Organization, \u201cdrug-resistant diseases could cause 10 million deaths each year by 2050 and force up to 24 million people into extreme poverty by 2030 if no action is taken.\u201d<\/p>\n

One of the primary reasons for the resistance crisis is the \u201cantibiotic discovery void\u201d that has plagued the scientific community for the past 34 years. According to the article, researchers discovered the last class of highly effective antibiotics in 1987 and no new antibiotics have made it out of the lab since. Professor Hudson posits that solving the resistance crisis will require more than just proper antibiotic use by individual doctors and patients, but rather will also require mutual investment and collaboration from the federal government, academia and pharmaceutical companies; a tactic that he calls \u201ccollaboration by triangulation.\u201d<\/p>\n

The first pillar of this model involves collaboration between basic scientists in academia, whose research will provide the foundational knowledge to discover new drugs, and pharmaceutical companies that have the infrastructure to produce and test these drugs at a scale that is not typically available at the academic level. The remaining 2 pillars of this plan involve financial and legislative support from the federal government \u2013 this includes more academic research funding and implementing policies that incentivize pharmaceutical investment in the development of new drugs.<\/p>\n

The Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act is a bipartisan bill that was proposed in June of 2021, and if passed into law would \u201cpay developers contractually agreed-upon amounts to research and develop antimicrobial drugs for a time period that ranges from five years up to the end of the patent.\u201d Professor Hudson urges that passage of this bill and monetary incentives are an \u201cimportant step in the right direction to address antibiotic resistance and the threat that it poses to human health in the U.S. and the world.\u201d<\/p>\n

Click here to read the full article.<\/a><\/p>\n

\n

\n<\/div><\/div>

TRADUCCI\u00d3N DE GOOGLE:<\/span><\/strong><\/p>\n

\n<\/div><\/div>

La resistencia a los antibi\u00f3ticos se encuentra en un punto cr\u00edtico: el apoyo del gobierno al mundo acad\u00e9mico y las grandes farmac\u00e9uticas para encontrar nuevos medicamentos podr\u00eda ayudar a derrotar a las superbacterias<\/strong><\/h3>\n

En un art\u00edculo publicado recientemente en The Conversation, el profesor Andre Hudson, director de la Escuela de Ciencias de la Vida Thomas H. Gosnell en el Instituto de Tecnolog\u00eda de Rochester, detall\u00f3 los pasos que cree que son importantes para combatir la creciente crisis de resistencia a los antibi\u00f3ticos que enfrentamos hoy. Las infecciones resistentes a los antibi\u00f3ticos representan 700.000 muertes al a\u00f1o en todo el mundo y, seg\u00fan un informe conjunto de las Naciones Unidas y la Organizaci\u00f3n Mundial de la Salud, \u201clas enfermedades resistentes a los medicamentos podr\u00edan causar 10 millones de muertes cada a\u00f1o para 2050 y llevar a 24 millones de personas a situaciones extremas. pobreza para 2030 si no se toman medidas “.<\/p>\n

Una de las principales razones de la crisis de resistencia es el “descubrimiento de antibi\u00f3ticos vac\u00edo” que ha plagado a la comunidad cient\u00edfica durante los \u00faltimos 34 a\u00f1os. Seg\u00fan el art\u00edculo, los investigadores descubrieron la \u00faltima clase de antibi\u00f3ticos altamente efectivos en 1987 y desde entonces no han salido nuevos antibi\u00f3ticos del laboratorio. El profesor Hudson postula que resolver la crisis de resistencia requerir\u00e1 m\u00e1s que el uso adecuado de antibi\u00f3ticos por parte de m\u00e9dicos y pacientes individuales, sino que tambi\u00e9n requerir\u00e1 una inversi\u00f3n mutua y la colaboraci\u00f3n del gobierno federal, el mundo acad\u00e9mico y las compa\u00f1\u00edas farmac\u00e9uticas; una t\u00e1ctica que \u00e9l llama “colaboraci\u00f3n por triangulaci\u00f3n”.<\/p>\n

El primer pilar de este modelo implica la colaboraci\u00f3n entre cient\u00edficos b\u00e1sicos del mundo acad\u00e9mico, cuya investigaci\u00f3n proporcionar\u00e1 el conocimiento fundamental para descubrir nuevos medicamentos, y las empresas farmac\u00e9uticas que tienen la infraestructura para producir y probar estos medicamentos a una escala que normalmente no est\u00e1 disponible en el \u00e1mbito acad\u00e9mico. nivel. Los 2 pilares restantes de este plan involucran el apoyo financiero y legislativo del gobierno federal; esto incluye m\u00e1s financiamiento para la investigaci\u00f3n acad\u00e9mica y la implementaci\u00f3n de pol\u00edticas que incentiven la inversi\u00f3n farmac\u00e9utica en el desarrollo de nuevos medicamentos.<\/p>\n

La Ley de Suscripciones Antimicrobianas Pioneras para Poner Fin a la Resistencia al Aumento (PASTEUR) es un proyecto de ley bipartidista que se propuso en junio de 2021, y si se promulga como ley, \u201cpagar\u00eda a los desarrolladores cantidades acordadas contractualmente para investigar y desarrollar medicamentos antimicrobianos por un per\u00edodo de tiempo que var\u00eda desde cinco a\u00f1os hasta el final de la patente “. El profesor Hudson insta a que la aprobaci\u00f3n de este proyecto de ley y los incentivos monetarios sean un “paso importante en la direcci\u00f3n correcta para abordar la resistencia a los antibi\u00f3ticos y la amenaza que representa para la salud humana en los EE. UU. Y el mundo”.<\/p>\n

Click here to read the full article.<\/a><\/p>\n

 <\/p>\n

\n

\n<\/div><\/div><\/div><\/div><\/div>

\n\n